* Says 75 pct achieved undetectable levels of virus
* Says ANA598 at 200 mg the most attractive agent
* Shares up 9 pct (Adds details, updates share movement)
May 21 (Reuters) - Anadys Pharmaceuticals Inc ANDS.O said its experimental hepatitis C drug showed positive early response rates in a mid-stage trial, sending its shares up as much as 9 percent.
The company said 75 percent of patients who received 400 milligrams of Anadys’ ANA598 twice daily for 12 weeks in combination with standard treatments achieved undetectable levels of the virus.
In February, the company said 73 percent of patients achieved undetectable levels of the virus in a similar study using a 200 mg dose of the drug. [ID:nN24199677]
However, 63 percent of patients who received a dummy drug with standard treatments showed undetectable levels of the virus.
Anadys said 56 percent of patients in the placebo control arm have the specific genotype that appears to respond most favorably to the standard treatment, while in the ANA598 treated arm 21 percent patients have that specific genotype.
“Coupled with the favorable tolerability profile seen at 200 mg bid, we believe that these results establish ANA598 at 200 mg bid as one of the most attractive agents in Phase 2 HCV development today,” Chief Executive Steve Worland said.
Anadys said both doses of ANA598 demonstrated a favorable safety and tolerability profile through 12 weeks.
Shares of the company were up 5 percent at $2.36 in morning trade Friday on Nasdaq. They touched a high of $2.45 earlier in the session. (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott and Don Sebastian)